Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eurofins Amatsigroup Rebrands to Eurofins CDMO | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eurofins Amatsigroup Rebrands to Eurofins CDMO

Provides integrated, end-to-end solutions for pre-clinical and clinical outsourcing services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

In 2017, Eurofins Scientific, a biopharmaceutical testing firm acquired Amatsigroup SAS to support Eurofins’ extensive drug development platform. Starting July 2, 2019 the commercial brand for Eurofins Amatsigroup is now Eurofins CDMO, falling under the contract development and manufacturing organization (CDMO) umbrella in conjunction with Eurofins’ operations in North America and India. Eurofins CDMO provides integrated, end-to-end solutions for pre-clinical and clinical outsourcing services of both drug substance/API and drug product manufacturing for biologics and small molecules.
 
Eurofins CDMO’s capabilities include:
 
• Supporting clients to move rapidly through the drug development value chain;
• Performing complex formulation screening and development for sterile and non-sterile manufacturing;
• Accelerating process development and scale-up under GMP compliance;
• Supplying clinical trial materials including packaging and logistics; and
• Provide regulatory compliance throughout each stage of the development cycle.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters